Skip to main content

Table 4 The summary of the measurement properties of cross-cultural the National Institutes of Health Chronic Prostatitis Symptom Index adaptations

From: A systematic review of cross-cultural adaptation of the National Institutes of Health Chronic Prostatitis Symptom Index

Language-population Internal consistency Construct validity Concurrent validity Agreement Reliability Responsiveness Floor and ceiling effects Discriminant validity
Original-American [7, 9,10,11] Total 0.82; Pain 0.65; Void 0.77; QOL 0.73 Pain location 0.35–0.88
Pain frequency 0.18–0.87
Pain severity 0.39–0.95
Void 0.32–0.73
Impact 0.32–0.94
Overall QOL 0.35–0.94
AUA symptom index: Pain 0.39; Void 0.87; QOL 0.46
GCPS Pain: Pain 0.61; Void 0.31; QOL 0.54; Total 0.60
GCPS Pain: Pain 0.38; Void 0.13; QOL 0.45; Total 0.40
0 Pain 0.83–0.93; Void 0.90; QOL 0.87–0.91 ROC curve 0.83 % Ceiling Effects (best possible score) 20.70 Pain CP/CPPS versus Healthy Individuals: 0.67
Original-Australian [12] 0 0 0 0 0 0 0 0
Original-Malaysian [13] Total 0.57; Pain 0.34; Void 0.32; QOL 0.33 0 IPSS Total 0.63; Pain 0.23; Void 0.85; QOL 0.44   Total 0.89; Pain 0.89; Void 0.84; QOL 0.85 0 0 CP/CPPS versus Healthy Individuals: Total 1.00; Pain 1.00; Void 0.87; QOL 1.00
CP/CPPS versus BPH: Total 0.; Pain 0.99; Void 0.39; QOL 0.75
Original-Spanish [14] Total 0.86; Pain 0.86; Void 0.79; QOL 0.87 Total 0.89–0.97; Pain 0.80–0.97; Void 0.76–0.89; QOL 0.76–0.94 0 0 0 0 0 0
Arabic-Egyptian [22] Total 0.92; Pain 0.89; Void 0.92; QOL 0.87 0 0 0 Total 0.90; Pain 0.84; Void 0.92; QOL 0.94 0 0    CPPS Controls P
Total 22.3(4.1) 2.3(2.8)  < 0.001
Pain 9.3(2.5) 0.6(0.2)  < 0.001
Void 3.7(1.8) 0.7(0.4)  < 0.001
QOL 7.3(2.4) 0.7(0.2)  < 0.001
Chinese-Mainland [23] Total 0.61; Pain 0.71; Void 0.59; QOL 0.75 0 0 0 Total 0.98; Pain 0.98; Void 0.98; QOL 0.97 0 0    CPPS Controls P
Total 23.33(5.91) 1.95(1.97) 0.00
Pain 8.80(4.26) 0.37(1.03) 0.00
Void 5.30(2.82) 0.15(0.58) 0.00
QOL 9.23(1.90) 1.42(1.20) 0.00
Chinese-Malaysian [13] Total 0.63; Pain 0.33; Void 0.73; QOL 0.60 0 IPSS Total 0.72; Pain 0.35; Void 0.78; QOL 0.29 0 Total 0.9; Pain 0.80; Void 0.82; QOL 0.77 0 0 CP/CPPS versus Healthy Individuals: Total 1.00; Pain 1.00; Void 0.90; QOL 0.99
CP/CPPS versus BPH: Total 0.87; Pain 0.96; Void 0.47; QOL 0.68
Danish [24] 0 0 0 No signs of systematic bias in Bland Altman Plot Total 0.93 (0.91–0.96); Pain 0.88 (0.84–0.92); Void 0.91 (0.88–0.94); QOL 0.93 (0.91–0.96) 0 0 0
Estonian [25] Total 0.82; Pain 0.67; Void 0.63; QOL 0.78 Total 0.62–0.93; Pain 0.35–0.92; Void 0.35–0.62; QOL 0.47–0.93 0 0 0 0 0    CPPS Controls P
Total 15.3 (5.6) 6.0 (6.7)  < 0.001
Pain 8.6 (2.5) 2.2 (3.3)  < 0.001
Void 1.2(1.4) 1.3 (1.9) 0.86
QOL 6.1 (2.1) 2.5(3.0) 0.001
Finnish [26] 0 Pain 0.36–0.89; Void 0.36–0.67; QOL 041–0.71 VAS Total 0.76; Pain 0.87; Void 0.27; QOL 0.60 0 0 0 0    CPPS Controls P
Total 20.2 (8.6) 5.8 (4.5)  < 0.001
Pain 9.9 (4.5) 0.1 (0.3)  < 0.001
Void 3.9 (3.1) 0.3 (0.6)  < 0.001
QOL 6.5 (2.9) 5.5 (4.3)  > 0.05
French-Canadian [27] Pain 0.807; Void 0.570; QOL 0.884 Pain 0.67–0.94; Void 0.55–0.67; QOL 0.62–0.0.97 SF− 12 Mental scale Pain − 0.29 to − 0.44; Void − 0.28 to − 0.43; QOL − 0.41 to − 0.51
SF− 12 Mental scale Pain − 0.32 to − 0.50; Void − 0.20 to − 0.37; QOL − 0.40 to − 0.59
0 0.352–0.862 0 0    CPPS Controls P
Pain 8.48 (4.67) 1.72 (2.27)  < 0.001
Void 3.33 (2.31) 0.95 (1.12)  < 0.001
QOL 5.39 (2.84) 0.76 (1.81)  > 0.05
German (1,2) [28, 29] Total 0.74; Pain 0.60; Void 0.69; QOL 0.67 Total 0.63–0.85 Pain 0.24–0.85; Void 0.24–0.63; QOL 0.32–0.77 0 0 0 0 0    NIH IIIA NIH IIIB P
Total 20(21.4) 24(23.9) 0.03
Pain 11(10.1) 12(11.3) 0.09
Void 3(3.2) 3(3.8) 0.14
QOL 8(8) 9(8.7) 0.16
Italian [30] Total 0.95; Pain 0.84; Void 0.96; QOL 0.86 0 VAS Total 0.80; Pain 0.88; Void 0.22; QOL 0.71
IPSS Total 0.55; Pain 0.27; Void 0.94; QOL 0.25
0 Total 0.90; Pain 0.83; Void 0.82; QOL 0.93 0 0    CPPS Controls P
Total 21.8 (8.5) 2.0 (2.8)  < 0.001
Pain 10.5 (4.5) 0.5 (1.2)  < 0.001
Void 4.5 (2.9) 0.9 (1.2)  < 0.001
QOL 6.8 (3.1) 0.6 (1.0)  < 0.001
Japanese (a) [31] 0 Pain 0.662; Void 0.531 0 0 0 0 0   CP/CPPS BPH Controls P
Pain 9.79 (3.10) 1.66 (3.05) 0.39 (0.92) 0.00
Void 3.82 (3.12) 3.29 (2.08) 0.72 (0.83) 0.00
QOL 8.21 (2.23) 4.17 (1.86) 1.39 (1.38) 0.00
Japanese (b) [32] Pain 0.83; Void 0.97; QOL 0.87 0 0 0 Pain 0.63; Urinary symptoms 0.91; QOL 0.72 0 0   CP BPH Controls P
Pain 9.0 (0–18) 1.0 (− 16) 0.0 (0–12) 0.00
Void 3.0 (0–10) 4.0 (0–10) 0.0 (0–8) 0.00
QOL 7.0 (2–11) 5.0 (0–12) 1.0 (0–6) 0.00
Malaysian [13] Total 0.62; Pain 0.43; Void 0.83; QOL 0.45 0 IPSS Total 0.49; Pain − 0.18; Void 0.87; QOL 0.16 0 Total 0.80; Pain 0.94; Urinary symptoms 0.87; QOL 0.85 0 0 CP/CPPS versus Healthy Individuals: Total 1.00; Pain 1.00; Void 0.83; QOL 0.98
CP/CPPS versus BPH: Total 0.94; Pain 0.96; Void 0.58; QOL 0.78
Persian [33] Total 0.865; Pain 0.853; Void 0.652; QOL 0.726 Total 0.666–0.889; Pain 0.389–0.889; Void 0.389–0.666; QOL 0.433–0.846 0 0 Total 0.901; Pain 0.894; Void 0.912; QOL 0.846 0 0    CP/CPPS Controls P
  Total 22.47(6.9) 2.1(2.7)  < 0.001
  Pain 10.35(3.7) 0.3(0.2)  < 0.001
  Void 4.73(1.98) 0.5(0.4)  < 0.001
  QOL 7.38(2.7) 0.8(0.4)  < 0.001
Portuguese-Brazilian [34] Pain 0.90; Void 0.85; QOL 0.93 0 0 0 Pain 0.89–0.94; Void 0.99; QOL 0.96–0.97 0 0 /
Spanish [14] Total 0.94; Pain 0.87; Void 0.81; QOL 0.86 Total 0.89–0.97; Pain 0.80–0.97; Void 0.76–0.89; QOL 0.76–0.94 0 0 0 0 0 /
Turkish [35] Total 0.864; Pain 0.862; Void 0.819; QOL 0.762 Total 0.66–0.77; Pain 0.25–0.72; Void 0.33–0.72; QOL 0.25–0.66 VAS Total 0.6; Pain 0.66; Void 0.22; QOL 0.29 0 Total 0.909; Pain 0.886; Void 0.925; QOL 0.874 IPSS Total 0.48; Pain 0.24; Void 0.54; QOL 0.4 0 0   CP/CPPS Controls P
Total 22.8 (7.7) 2.5 (1.7)  < 0.001
Pain 9.5 (4.8) 1.4 (1.2)  < 0.001
Void 6 (3.2) 0.6 (0.8)  < 0.001
QOL 7.3 (2.3) 0.5 (0.6)  < 0.001
  1. AUA, American Urological Association; GCPS, Graded Chronic Pain Scale; QOL, quality of life; ROC, Receiver Operating Characteristic; IPSS, International Prostate Symptom Scores; CP, chronic prostatitis; CPPS, chronic pelvic pain; BPH, benign prostatic hyperplasia; VAS, visual pain scale; SF-12, 12-item short-form Health Survey